<DOC>
	<DOCNO>NCT00958100</DOCNO>
	<brief_summary>This study aim verify persistent control virus replication 48 week simplification tenofovir + emtricitabine + raltegravir lamivudine+abacavir+raltegravir patient optimal virological suppression without virological failure previous combine antiretroviral therapy need therapeutic switch toxicity relate issue adverse event .</brief_summary>
	<brief_title>Raltegravir Switch Toxicity Adverse Events</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients treat combined antiretroviral therapy least 1 year Aged 18 year old With one follow condition : Grade 3 4 Dyslipidemia Any Hyperglycemia Lipodystrophy ( patient 's self report , confirm physician 's physical examination ) Moderate/severe cardiovascular risk , define calcium score high 40 Framingham score high 10 ( estimate 10 year cardiovascular risk : 10 % ) Diarrhea ( least 3 emission loose stool every day least 3 day every week ) With least two HIVRNA level &lt; 50 copies/mL two consecutive determination least 3 month apart With CD4 cell count &gt; 200 cells/ Î¼L least 6 month absence opportunistic infection AIDSrelated disease last year screening . Who give inform consent participation study Pregnancy breast feeding , desire pregnancy short term Previous virological failure ( two consecutive HIVRNA level &gt; 50 copies/mL single value &gt; 1000 copies/mL ) antiretroviral therapy and/or previous exposure mono dual therapy reverse transcriptase nucleoside analogues except patient subsequent genotypic resistance test show resistance mutation study drug . Previous exposure inhibitor HIV1 integrase Previous major toxicity study drug Spontaneous treatment interruption disagreement treat physician last year loss followup least 6 month , least last two year Current alcohol drug abuse condition , judgment treat physician , may impair patient 's adherence new drug regimen and/or protocol 's procedure Patients grade 3 4 laboratory abnormality screen ( except lipid glucose level )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>raltegravir switch toxicity</keyword>
	<keyword>treatment experience</keyword>
</DOC>